Missed Aveanna Healthcare's Run? What Holders Had To Believe

If Aveanna Healthcare had been on your watchlist instead of in your account, the move over this year might feel like a missed shot. For Aveanna Healthcare shareholders, the return from the start of the year was 64.0%, including dividends. That surge arrived as Q2 2026 results showed higher revenue, higher profit, and a wider net margin than Q2 2025. If you were sizing it up back on 1 January 2026, how confident could you really have been that earnings visibility and liquidity shifts would support this kind of payoff?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

This theme extends beyond Aveanna Healthcare. See which of 35 healthcare AI stocks may still merit a closer look.

The Two Aveanna Healthcare Stories Investors Had To Weigh

The shares cost US$8.17 at the start of the period, and Aveanna Healthcare sat between two sharply different stories about what might come next.

On the optimistic side, one narrative saw improved earnings visibility and stronger liquidity supporting capacity expansion, with a Fair Value of US$8.81, which is 8% above the start price. That view leaned on assumptions of 7.2% revenue growth and a 6.2% profit margin over three years.

The more pessimistic case carried a Fair Value of US$6, which is 27% below the start price. It focused on risks that Medicaid cuts and rising wages would erode profitability, even if revenue grew 6.8% with a 4.6% margin assumption.

What The Results Changed For The Aveanna Healthcare Story

The key update for Aveanna Healthcare was Q2 2026, when revenue reached US$670.5m and net income excluding extra items was US$40.3m. Both figures were higher than Q2 2025 and net margin moved from 4.6% to 6.0%. That profitability level sat closer to the optimistic thesis than the cautious case, although regulatory and funding risks from the original bear story were not resolved.

The decision here ultimately hinged on whether earnings quality and margins would follow the optimistic script. When you assess another healthcare stock, track how its reported margin and guidance compare with the thesis that originally justified the fair value you used.

What Aveanna Healthcare's Run Leaves You Paying For Now

Aveanna Healthcare now trades at US$13.25 from the start of the year, and the bullish analyst Narrative on Simply Wall St still places its Fair Value above that level. The Narrative leans heavily on execution in pediatric preferred payer contracts, AI supported back office work, and cash generation.

On that view, the current quote does not yet fully credit Aveanna Healthcare using future free cash flow and lower leverage to fund acquisitions, mix shifts and other reinvestment choices that support its pediatric focused home care model.

"The main factor that has to go right is continued execution on preferred payer penetration, pediatric PDN staffing and reimbursement alignment, and disciplined use of growing free cash flow while managing a still meaningful debt load."

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all

Which Company Could Surprise You Next?

The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?

• Company 1 - 18% below our estimate - supplies high-bandwidth memory that enables AI accelerators and data centers.
• Company 2 - 42% below our estimate - rolls out cash recycling ATMs and compact branch-in-a-box banking systems.
• Company 3 - 36% below our estimate - expands app driven coffee ordering and rapid openings of dense urban storefronts.

Three companies from the same screener. Open all 40 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com